The future for the biotechnology industry in Japan is bright. The Japanese government has made great strides to boost biotech within its borders. According to the Scientific American Worldview Report and Scorecard, Japan has held steady in its global innovation ranking among other countries over the past three years. In 2011, Japan ranked #11 among other top countries for biotechnology, with strong scores in the number of patents the country produces as well as overall innovation.

 

  1. The new law to activate Regenerative Medicine itself and related business was made and enacted. Last year two regenerative medicine business models got approval from governmental authority and the cost for those business was decided to be covered by national insurance. 
  2. The Ministry of Health, Labour and Welfare has introduced “Sakigake” package. This scheme is to develop and approve cutting edge drugs with less time. This is to aim development of new drugs ahead of others in Japan.
  3. The new governmental body called AMED (which stands for Japan Agency for Medical Research and Development) is established last year. This is a kind of the control tower of Japan’s healthcare research and development policy. AMED started their activities to stimulate healthcare research and development in Japan.

Market Facts

  • Researchers at Japanese universities have contributed to drug discovery including therapies treating Multiple Sclerosis and Rheumatoid Arthritis.
  • The discovery of iPS (induced pluripotent stem) cells and Dr. Shinya Yamanaka, Kyoto University wins the Novel Prize in Physiology or Medicine in 2012.
  • The new law to activate Regenerative Medicine itself and related business was enacted. In 2016, two regenerative medicine business models got approval from the governmental authority and the cost for those business will be covered by national insurance. 
  • The Ministry of Health, Labour and Welfare has introduced “Sakigake” package. This scheme is to develop and approve cutting edge drugs with less time. 
  • The new governmental body called AMED (Japan Agency for Medical Research and Development) was established in 2016. This is a kind of control tower for Japan’s healthcare research and development policy. AMED started their activities to stimulate healthcare research and development in Japan.

Japan BioIndustry Association (JBA)

Japan Bioindustry Association (JBA) is a non-profit organization established in 1987. The organization is planning for sound development in bioscience-related industries and is dedicated to solving problems on a global scale through advances in bioscience. JBA is contributing to society in various areas from the development of advanced technology to the development of industry. Japanese bioindustries have developed with a base in the traditional fermentation industry. However in recent years advances in biotechnology have been made in various fields and this in turn has had an impact on numerous corporations.

JBA’s membership base spans a wide array of corporations that use applications of biotechnology in areas ranging from pharmaceutical and medical supplies, food and cosmetics, as well as chemicals, information, machinery, construction and energy and natural resources. In addition, JBA counts public organizations, universities, public research institutes and a variety of individuals as members. Hence JBA is a unique organization able to comprehensively promote the advancement of bioindustries through the cooperation of industry, academia and government.

Association’s resources

  • Research at Japanese Universities

    Researchers at Japanese universities have made significant strides in biotechnology innovation. This handout lists some of those notable contributions.

    See Publication
  • Japan’s Bioeconomy Vision Outline

    JBA’s position paper on the bioindustry’s contributions and potential solutions towards solving global health challenges.

    See Publication